Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 8;10(3):e004281. doi: 10.1136/jitc-2021-004281

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Comparative T cell-redirected killing of HLA/peptide⁺ tumor cell lines via the rTCR/anti-CD3 BFPs. BFP-induced redirection of naïve T cells to kill HLA-A1⁺ HCT116 colorectal cancer cells (A) or HLA-A2⁺ Saos-2 osteosarcoma cells (B) preincubated with MAGE-A3_168–176 EVDPIGHLY or NY-ESO-1_157–165 SLLMWITQC peptides, respectively. BFP-induced killing of HLA-A1⁺/MAGE-A3⁺/HLA-A2⁺/NY-ESO-1⁻ HCT116 cells (C) or HLA-A1⁺/MAGE-A3⁺/HLA-A2⁺/NY-ESO-1⁺ A375 malignant melanoma cells (D) using preactivated T cells. BFP, bifunctional protein; E:T, effector cell to tumor cell ratio; rTCR, recombinant T cell receptor-based therapeutic; TCR, T cell receptor.